NHS Faces Massive New Fat Jab Bill

Written by Harry Turnbull

The NHS is poised to spend hundreds of millions of pounds expanding access to the weight loss drug Wegovy in the hope it can also prevent heart attacks and strokes.

Drugs watchdog NICE has approved its use for those at risk from a cardiac event but the decision is based on evidence that has come under heavy criticism for being incomplete.

NICE fast-tracked a decision, relying on a single clinical trial conducted by the drug maker Novo Nordisk which showed that 67 people need to be treated for 34 months to prevent one major cardiovascular event. The company has also confessed it needs further research to determine just how the medication Semaglutide (brand name Wegovy) improves heart health.

The treatment will be offered to 1.2m people with a cardiac risk profile and a BMI of at least 27. Costs are being kept confidential but could easily run into hundreds of millions, even billions of pounds to have a weekly injection.

The NHS says it could be a ‘life-changing’ treatment and claimed it would slash risk by 20% but critics point out this is relative risk – a way of inflating the impact of a drug. In the SELECT trial involving 17,600 patients:

  • 8.0% of in the placebo group suffered a heart-related event.
  • 6.5% of taking Wegovy suffered a heart-related event.

That 1.5 percentage point difference represents their 20% relative reduction figure. The real reduction is just 1.5% or 1 in 67 benefited.

Callum McGoldrick, investigations campaign manager at the TaxPayers’ Alliance, commented:

“Taxpayers should be deeply concerned that the NHS may be committing billions to a drug whose benefits have been sold with flattering headline statistics and opaque evidence.”

David Phizackerley, former deputy editor at the BMJ’s Drugs and Therapeutics Bulletin, noted:

“Unfortunately, many news stories focus on the relative figure rather than the absolute risk of 1.5%—or the fact that 67 people need to be treated for 34 months to prevent one single event.”

Cheshire-based physician Dr. Malcolm Kendrick, author of a book on medical statistics called Doctoring Data, argues that producing a hypothesis that Wegovy improves cardiovascular circulation independent of weight loss needs much more scrutiny and research.

Bizarrely the trial called SELECT failed to find a connection between weight loss and improved cardiovascular health, something that is more or less taken for granted and is why Kendrick is calling for more research.

Dr. Wilding

But Dr John Wilding of Liverpool University, former president of the World Obesity Federation, supports the NHS investment in Wegovy:

“The group of people who are likely to benefit most are at high risk of diabetes; in the SELECT trial the number needed to treat for diabetes prevention was 18, and complete normalisation of blood glucose was seen in nearly 70% of people treated with Semaglutide compared to 35% with placebo. 

“We also would expect to see less fatty liver disease, less sleep apnoea, less pain from knee arthritis (and potentially a lower need for knee replacement). These benefits need to be considered as a whole, not just looking at one thing.”

Novo Nordisk stated:

“SELECT was a large, randomised, double-blind cardiovascular outcomes trial, and Novo Nordisk stands behind the integrity of the study and its published results. We support transparency and continue to work closely with regulatory and health technology assessment bodies, like NICE and NHS England to ensure they have the data needed to assess our medicines appropriately.”

NHS England declined to comment.

About the author

Harry Turnbull is a freelance journalist working in the North of England